The papillary carcinoma uses thyroglobulin as a tumor marker which is highly sensitive but not specific, CD56 was used in one-third of the cases of papillary cancers where its negativity was highly sensitive, as it was not applied in other variants so specificity could not be assessed. This evidence concerns the gene NCAM1 and neoplasm.